-
Roche’s Lymphoma Therapy Columvi Receives NMPA Approval for Adult Patients with Relapsed DLBCL
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received market approval from the National Medical Products Administration (NMPA) in China for its novel lymphoma therapy, Columvi (glofitamab). The drug is now approved to treat adult patients with recurrent or refractory diffuse large B-cell lymphoma (DLBCL) who have…
-
Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004
•
Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene’s GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes,…
-
Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance
•
Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of…
-
Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis
•
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for Tremfya (guselkumab), an IL-23p19-subunit inhibitor, in the treatment of treatment-resistant active psoriatic arthritis (PsA). The data provides valuable insights into the drug’s performance in alleviating pain, improving physical function, and reducing fatigue in patients with…
-
Zhejiang Boner Medical Secures Over RMB 800 Million in Pre-IPO Financing for Strategic Expansion
•
Zhejiang Boner Medical Investment Management Co., Ltd., known as Bang-er Orthopedics, a leading hospital investment operator focused on orthopedics and rehabilitation, has reportedly raised over RMB 800 million (USD 110 million) in a pre-IPO financing round. The round was led by C&D Emerging Industry Equity Investment, with participation from Sunshine…
-
ImmuneOnco Biopharmaceuticals’ Timdarpacept (IMM01) Earns Orphan Drug Designation for CMML
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug timdarpacept (IMM01). This marks a significant milestone for the company’s first SIRPαFc fusion protein targeting CD47, which was designed in China.…
-
Lifetech Scientific Corporation Receives NMPA Approval for Peripheral Thrombus Suction Catheter
•
Lifetech Scientific Corporation (HKG: 1302), a China-based medical device company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its innovative peripheral thrombus suction catheter. This device is designed for the removal of thrombi from the peripheral arterial and venous vascular systems, offering…
-
Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth
•
Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023, revealing global sales of EUR 35.8 billion (USD 38.3 billion) between Q1 and Q3, marking a 3.2% year-on-year (YOY) decline. Despite this, the company confirmed its 2023 guidance of EUR 48.5 billion to EUR 49.5…